^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19-targeted CAR-T immunotherapy

    Related drugs:
    24h
    Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL (clinicaltrials.gov)
    P1, N=19, Recruiting, University Health Network, Toronto | Trial completion date: May 2026 --> Jun 2028 | Trial primary completion date: Mar 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    1d
    A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, Gracell Biotechnologies (Shanghai) Co., Ltd. | Recruiting --> Active, not recruiting | N=118 --> 20
    Enrollment closed • Enrollment change
    |
    AZD0120
    1d
    Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=20 --> 9
    Enrollment closed • Enrollment change
    |
    clonoSEQ®
    |
    Opdivo (nivolumab) • Imbruvica (ibrutinib) • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    1d
    ZeTA: A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T (clinicaltrials.gov)
    P2, N=76, Recruiting, University Health Network, Toronto | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Apr 2026 --> Apr 2029
    Trial completion date • Trial primary completion date
    |
    Tevimbra (tislelizumab-jsgr) • Brukinsa (zanubrutinib)
    1d
    Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    pomalidomide
    1d
    SCLEROCAR: Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy (clinicaltrials.gov)
    P2, N=6, Not yet recruiting, University Hospital, Montpellier | Trial completion date: Apr 2028 --> Aug 2028 | Initiation date: Apr 2026 --> Aug 2026 | Trial primary completion date: Apr 2026 --> Aug 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    2d
    T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    cyclophosphamide • vadacabtagene leraleucel (JCAR015)
    5d
    A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=439, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2029 --> Jul 2041
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    5d
    Understanding access to novel high-cost cancer therapies across Canada: a national survey of pediatric oncology providers. (PubMed, Front Pediatr)
    Vignettes explored access to evidence-informed but not universally funded therapies: blinatumomab for low-risk relapse of B-cell acute lymphoblastic leukemia (B-ALL), larotrectinib for TRK-fused soft tissue sarcoma, PBT for unresectable head-and-neck sarcoma, and tisagenlecleucel for first relapse of B-ALL in a patient with Down syndrome. Access to evidence-informed cancer therapies for Canadian children remains variable. Universal funding, simplified approval processes, and the establishment of Canadian PBT centres to reduce travel burden, would ensure timely, equitable access to high-cost therapies.
    Journal
    |
    TFG (Trafficking From ER To Golgi Regulator)
    |
    Vitrakvi (larotrectinib) • Blincyto (blinatumomab) • Kymriah (tisagenlecleucel-T)
    5d
    Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=24, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    Erbitux (cetuximab) • cyclophosphamide • fludarabine IV • CD19 CAR T cells
    6d
    SZ4601: CAR-T Cell Therapy Targeting to CD19 for R/R ALL (clinicaltrials.gov)
    P1/2, N=196, Active, not recruiting, The First Affiliated Hospital of Soochow University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cyclophosphamide • fludarabine IV
    6d
    Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Hrain Biotechnology Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> May 2027
    Enrollment closed • Trial completion date
    |
    CD22 (CD22 Molecule) • IL15 (Interleukin 15)
    |
    CD22 positive
    |
    anti-CD19/CD22 CAR-T cells